羟基喜树碱治疗非小细胞肺癌的临床研究

Clinical Study on Treatment of Non-Small Cell Lung Cancer with 10-Hydroxycamptothecin

目的:观察拓扑异构酶Ⅰ、Ⅱ抑制剂按时间顺序给药的临床疗效及不良反应。方法:观察组化疗方案为HP-EP-HP-EP,对照组为CAP-EP-CAP-EP。HCPT10～12mg/m2静推d1～5,DDP80mg/m2ivgtt分3天使用,VP-16100mg/m2ivgttd1,3,5,ADM40mg/m2静推d1,CTX400mg/m2静推d1,d8。上述方案每3周为1周期,交替使用,4个周期为一观察疗程。结果:观察组60例患者完成一个疗程具有可评价者54例,有效率51.85%;对照组60例患者完成一个疗程具有可评价者58例,有效率32.76%,两组间有显著性差异(P<0.05)。不良反应:两组均出现血象下降、消化道反应、脱发等,两组间无显著性差异(P>0.05)。结论:观察组疗效确切,不良反应可以耐受,说明拓扑异构酶Ⅰ、Ⅱ抑制剂按时间顺序给药有较好疗效,具有一定的临床应用价值。

Objective:To study the clinical response and adverse reactio n ofⅠandⅡtopoisomerase inhibitors given to the patients with non-small lung c ancer.Methods:Test group:HP-EP-HP-EP,Control group:CAP-EP-CAP-EP,HCP T10-12mg /m 2 iv bolus.D1-5.DDP80mg/m 2 iv drip.They were used for3days.VP-16100mg/m 2 iv drip d1,3,5.ADM40mg/m 2 iv bolus d1.CTX400mg /m 2 iv bolus d1,d8.Repeated3weeks for1cycle.Results:There were54valuab le cases in60cases who have finished1therapeutic course with an effec tive ra te of51.85%.In the control group,there were58valuable cases in60case s who have fin-ished1therapeutic course with an effective rate of32.76% .There was significant difference be-tween these two groups(P<0.05). The main side-effects included leukopenia,G-I reactions and alopecia.Conclu sion:The outcome of the test group shows that topoisomeraseⅠandⅡin-hibitor s can produce good curative effect in the treatment of non-small cell lung can cer.